The acquisition has been finalized. Parties agreed not to disclose financial details of the acquisition. The impact of the acquisition on DSM's net sales in 2009 and 2010 is not expected to be material.

Founded in 1992, Biopract's main focus has been on the commercialization and extension of their Methaplus(TM) enzyme series for the improvement of agricultural and industrial biogas production. The company has a strong application and technology position in this field.

Rob van Leen, Chief Innovation Officer of DSM said: "We are convinced that biotechnology will contribute significantly to the sustainable and efficient use of natural resources today and in the future. We look forward to combining Biopract's expertise with ours to further increase the efficiency and performance of biogas plants."

Biogas is produced by anaerobic fermentation of biodegradable materials such as biomass, manure or sewage, green waste and energy crops. It can be used to generate electricity and as a low-cost fuel for any heating purpose. Biogas can also be upgraded to natural gas quality.

Driven by climate change and alternative energy initiatives, the market for production and optimization of biogas-related processes will become significant in the coming years. The acquisition of Biopract will accelerate DSM's growth in this market.

Biopract's activities will be integrated into DSM's biogas service concept for optimizing the biotechnology of biogas plants. Based on a thorough analysis of the production process, DSM offers agricultural and industrial biogas plants tailor-made advice and a product mix to improve the biotechnology process and to increase the performance of the plant.

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

For more information:

DSM Corporate Communications

Herman Betten

tel. +31 (0) 45 5782017           

fax +31 (0) 45 5740680           

e-mail media.relations@dsm.com  

DSM Investor Relations

Hans Vossen

tel. +31 (0) 45 5782864

fax +31 (0) 45 5782595

e-mail investor.relations@dsm.com

Press release-pdf

Forward-looking statements

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.

The English language version of the press release is leading.